Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition?


      To describe the pharmacokinetics, preclinical studies, and clinical trials of the newly approved anti–vascular endothelial growth factor (VEGF) drug aflibercept (Eylea (VEGF Trap-Eye); Regeneron; and Bayer).


      Review with editorial commentary.


      A review of the medical literature and pertinent Internet postings combined with analysis of key studies with expert opinion regarding the use of aflibercept for the treatment of exudative age-related macular degeneration.


      Aflibercept, a fusion protein with binding domains from native VEGF receptors, binds VEGF-A, VEGF-B, and placental growth factors 1 and 2 with high affinity. Preclinical ophthalmologic studies demonstrated that aflibercept suppresses choroidal neovascularization in several animal models. The results of phase 1 and 2 trials showed excellent short-term suppression of choroidal neovascularization in patients with exudative age-related macular degeneration and suggested a longer durability of aflibercept compared with other anti-VEGF drugs. The pivotal phase 3 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration 1 and 2 trials showed that monthly and bimonthly aflibercept were noninferior to monthly ranibizumab at preventing vision loss (< 15-letter loss) with comparable vision gains and safety. Year 2 treatment involved monthly pro re nata injections with required injections every 3 months and maintained vision gains from the first year, with an average of 4.2 injections of aflibercept and 4.7 injections of ranibizumab.


      Aflibercept promises to deliver excellent visual outcomes for exudative age-related macular degeneration patients while undergoing fewer injections compared with ranibizumab. With a wholesale cost of $1850 per dose, the cost per patient with aflibercept treatment promises to be lower than with ranibizumab.
      To read this article in full you will need to make a payment


        • Ferrara N.
        • Damico L.
        • Shams N.
        • et al.
        Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
        Retina. 2006; 26: 859-870
        • Holash J.
        • Davis S.
        • Papadopoulos N.
        • et al.
        VEGF-Trap: a VEGF blocker with potent antitumor effects.
        Proc Natl Acad Sci U S A. 2002; 99: 11393-11398
        • Papadopoulos N.
        • Martin J.
        • Run Q.
        • et al.
        Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
        Angiogenesis. 2012; (Forthcoming)
        • Stewart M.W.
        What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes?.
        Eye Reports. 2011; 1: e5
        • Stewart M.W.
        • Rosenfeld P.J.
        Predicted biological activity of intravitreal VEGF Trap.
        Br J Ophthalmol. 2008; 92: 667-668
        • Yu L.
        • Liang X.H.
        • Ferrara N.
        Comparing protein VEGF inhibitors: in vitro biological studies.
        Biochem Biophys Res Commun. 2011; 408: 276-281
        • Stewart M.W.
        Aflibercept (VEGF-Trap): the next anti-VEGF drug.
        Inflamm Allergy Drug Targets. 2011; 10: 497-508
        • Kim E.S.
        • Serur A.
        • Huang J.
        • et al.
        Potent VEGF blockade causes regression of co-opted vessels in a model of neuroblastoma.
        Proc Natl Acad Sci U S A. 2002; 99: 11399-11404
        • Wang T.-F.
        • Lockhart A.C.
        Aflibercept in the treatment of metastatic colorectal cancer.
        Clin Med Insights Oncol. 2012; 6: 19-30
        • Saichin Y.
        • Saichin Y.
        • Takahashi K.
        • et al.
        VEGF-trapR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
        J Cell Physiol. 2003; 195: 241-248
        • Joussen A.M.
        • Poulaki V.
        • Qin W.
        • et al.
        Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.
        Am J Pathol. 2002; 160: 501-509
        • Cao J.
        • Zhao L.
        • Li Y.
        • et al.
        A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap.
        Invest Ophthalmol Vis Sci. 2010; 51: 6009-6017
        • Inai T.
        • Mancuso M.
        • Hashizume H.
        • et al.
        Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
        Am J Pathol. 2004; 165: 35-52
        • Nguyen Q.D.
        • Shah S.M.
        • Hafiz G.
        • et al.
        • CLEAR-AMD 1 Study Group
        A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
        Ophthalmology. 2006; 113: 1522-1532
        • Nguyen Q.D.
        • Shah S.M.
        • Browning D.J.
        • et al.
        A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.
        Ophthalmology. 2009; 116: 2141-2148
        • Brown D.M.
        • Heier J.S.
        • Ciulla T.
        • et al.
        • CLEAR-IT 2 Investigators
        Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.
        Ophthalmology. 2011; 118: 1089-1097
        • Heier J.S.
        • Boyer D.
        • Nguyen Q.D.
        • et al.
        • CLEAR-IT 2 Investigators
        The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.
        Ophthalmology. 2011; 118: 1098-1106
        • Regeneron Pharmaceuticals, Inc.
        Bayer and Regeneron report positive top-line results of two phase 3 studies with VEGF Trap-Eye in wet age-related macular degeneration.
        (Accessed April 13, 2012)
        • Regeneron Pharmaceuticals, Inc.
        Two year results of phase 3 studies with EYLEA (aflibercept) injection in wet AMD show sustained improvement in visual acuity.
        (Accessed April 13, 2012)
        • Brechner R.J.
        • Rosenfeld P.J.
        • Babish J.D.
        • Caplan S.
        Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
        Am J Ophthalmol. 2011; 151: 887-895e1
        • Martin D.F.
        • Maguire M.G.
        • Ying G.-S.
        • et al.
        Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
        N Engl J Med. 2011; 364: 1897-1908
        • United States Special Committee on Aging
        A prescription for savings: reducing drug costs to medicare. Testimony before the Senate Special Committee on Aging by Philip J. Rosenfeld, MD, PhD.
        (Accessed April 13, 2011)